114 completed, 53 recruiting, 52 terminated, 51 unknown. 164 Phase 2, 92 Phase 1, 53 Phase 3, 17 Not applicable, 4 Early Phase 1.
Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | University of Nebraska | 50 | 2026-12-12 | 2026-11-06 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0920 - Diffuse Large B-Cell Lymphoma, B-cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-12-11 | 2026-10-21 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies BG-T0050 - Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | Phase 1 | Not yet recruiting | BeOne Medicines | 70 | 2026-11-30 | 2026-10-19 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 4 | Recruiting | The First Hospital of Jilin University | 26 | 2026-10-15 | 2026-11-02 |
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections Diffuse Large B-Cell Lymphoma | Not yet recruiting | AbbVie | 175 | 2026-10-02 | 2026-10-07 | |
| A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP Polatuzumab vedotin, Glofitamab - Diffuse Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Yonsei University | 47 | 2026-09-01 | 2026-07-14 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Penpulimab, Rituximab, Methotrexate - Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma | Not applicable | Not yet recruiting | WEI XU | 58 | 2026-08-01 | 2026-08-14 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission Chidamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Rong Tao | 69 | 2026-06-16 | 2026-06-18 |
| Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma CY-219 CAR-T - Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-05-01 | 2026-04-20 |
| Hyperfractionated Dual Equivalent Fractionated Radiation Therapy Bridging Radiation Therapy - Diffuse Large B-Cell Lymphoma | Not applicable | Recruiting | Yale University | 10 | 2025-10-30 | 2026-06-22 |
| An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma Glofitamab - Diffuse Large B-Cell Lymphoma | Recruiting | Hoffmann-La Roche | 300 | 2025-09-29 | 2026-11-05 | |
| G-Pola-ZLP in Diffuse Large B-Cell Lymphoma Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | Navy General Hospital, Beijing | 80 | 2025-09-24 | 2025-08-14 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 150 | 2025-08-19 | 2026-04-01 |
Showing 20 of 330. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (330) · Lymphoma, Non-Hodgkin (38) · Lymphoma, Follicular (36) · Lymphoma (35) · Lymphoma, Mantle-Cell (34) · Recurrence (29) · Leukemia, Lymphocytic, Chronic, B-Cell (28) · Burkitt Lymphoma (17) · Lymphoma, B-Cell, Marginal Zone (14) · Multiple Myeloma (14) · Hodgkin Disease (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Waldenstrom Macroglobulinemia (11) · Leukemia, Myeloid, Acute (10) · Lymphoma, B-Cell (10)
Hemic and Lymphatic Diseases (330) · Immune System Diseases (330) · Neoplasms by Histologic Type (330) · Immunoproliferative Disorders (329) · Lymphatic Diseases (328) · Lymphoproliferative Disorders (328) · Lymphoma, B-Cell (320) · Neoplasms (320) · Lymphoma (295) · Lymphoma, Non-Hodgkin (292) · Pathologic Processes (59) · Pathological Conditions, Signs and Symptoms (59) · Disease Attributes (55) · Hematologic Diseases (45) · Leukemia (34)
Rituximab (116) · Cyclophosphamide (61) · Prednisone (52) · Vincristine (48) · Doxorubicin (44) · Lenalidomide (34) · Etoposide (22) · polatuzumab vedotin (22) · Gemcitabine (21) · Oxaliplatin (16) · Bendamustine Hydrochloride (13) · Dexamethasone (13) · tafasitamab (12) · deltacortene (10) · zanubrutinib (10)
Novartis Pharmaceuticals (13) · Hoffmann-La Roche (12) · Ruijin Hospital (9) · Genmab (8) · National Cancer Institute (NCI) (7) · Fondazione Italiana Linfomi - ETS (6) · Fred Hutchinson Cancer Center (6) · Fudan University (6) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (6) · ADC Therapeutics S.A. (5) · AbbVie (5) · Merck Sharp & Dohme LLC (5) · Pfizer (5) · Second Affiliated Hospital, Zhejiang University, School of Medicine (5) · Gilead Sciences (4)
United States (149) · China (90) · Italy (54) · Spain (54) · France (50) · United Kingdom (41) · South Korea (34) · Canada (32) · Australia (29) · Belgium (29) · Germany (29) · Poland (29) · Czechia (24) · Austria (22) · Israel (22)
Brenda Sandmaier (3) · Christopher J Melani, M.D. (3) · Umberto Vitolo, MD (3) · Ye Guo, MD (3) · Carlos Grande, MD (2) · Cheolwon Suh, MD, PhD (2)
PMID 34515338, PMID 39319495, PMID 40802906, PMID 30770362, PMID 32499241, PMID 32817282, PMID 34634256, PMID 37369099, PMID 38775302, PMID 42699559, PMID 17242396, PMID 18213528, PMID 18559976, PMID 18824292, PMID 1950172, PMID 20548096, PMID 20686505, PMID 21390126, PMID 21482186, PMID 21495023, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 22851565, PMID 22882209, PMID 23144193, PMID 23247661, PMID 23799873, PMID 23834234, PMID 23955074, PMID 24352795, PMID 24403232, PMID 24625556, PMID 24721323, PMID 25361987, PMID 25475080, PMID 25514302, PMID 25652253, PMID 25696919, PMID 25712263, PMID 26232170, PMID 26341814, PMID 26373676, PMID 26755709, PMID 26968534, PMID 27063977, PMID 27063978, PMID 27093976, PMID 27209293
2023 (7), 2018 (5), P30CA015704 (5), 2014 (3), 2015 (3), 2016 (3), 2017 (3), 2019 (3), P01CA078902 (3), 2008 (2), 2009 (2), P30CA022453 (2), P30CA033572 (2), P30CA060553 (2), 2004 (1)